Human Glioblastoma Multiforme: p53 Reactivation by a Novel MDM2 Inhibitor

p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3

(2012) William H. Chappell et al.   CELL CYCLE

Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: Evidence from a systematic review and meta-analysis

(2012) Jiangbo Liu et al.   EUROPEAN JOURNAL OF CANCER

Targeted delivery of a novel palmitylated D-peptide for antiglioblastoma molecular therapy

(2012) Chong Li et al.   JOURNAL OF DRUG TARGETING

p53 Modulation as a Therapeutic Strategy in Gastrointestinal Stromal Tumors

(2012) Joern Henze et al.   PLoS One

CaMK4 Gene Deletion Induces Hypertension

(2012) Gaetano Santulli et al.   Journal of the American Heart Association

A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors

(2011) J. Tabernero et al.   CLINICAL CANCER RESEARCH

Anticancer effects of the p53 activator nutlin-3 in Ewing’s sarcoma cells

(2011) Jürgen Sonnemann et al.   EUROPEAN JOURNAL OF CANCER

Activation of p53 by Nutlin-3a Induces Apoptosis and Cellular Senescence in Human Glioblastoma Multiforme

(2011) Ruth Villalonga-Planells et al.   PLoS One

MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function

(2010) Asfar S. Azmi et al.   EUROPEAN JOURNAL OF CANCER

Identification of the Spiro(oxindole-3,3′-thiazolidine)-Based Derivatives as Potential p53 Activity Modulators

(2010) Isabel Gomez-Monterrey et al.   JOURNAL OF MEDICINAL CHEMISTRY

Automated Network Analysis Identifies Core Pathways in Glioblastoma

(2010) Ethan Cerami et al.   PLoS One

Genetic alterations and signaling pathways in the evolution of gliomas

(2009) Hiroko Ohgaki et al.   CANCER SCIENCE

A new synthetic protein, TAT-RH, inhibits tumor growth through the regulation of NFκB activity

(2009) Daniela Sorriento et al.   Molecular Cancer

Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy

(2008) Sanjeev Shangary et al.   Annual Review of Pharmacology and Toxicology

Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer

(2008) Sanjeev Shangary et al.   MOLECULAR CANCER THERAPEUTICS